Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Rheumatoid arthritis

When should we use rituximab to treat RA?

Nature Reviews Rheumatology volume 7, pages 379–380 (2011)Cite this article

Subjects

A decade and a half of rapid progress in treating rheumatoid arthritis (RA) has left clinicians with many options, yet few validated guidelines on how best to use them. What difference will new recommendations on the use of rituximab make to clinical practice?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Yazici, Y. Treatment of rheumatoid arthritis: we are getting there. Lancet 374, 178–180 (2009).

    Article  Google Scholar 

  2. Buch, M. H. et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 70, 909–920 (2011).

    Article  CAS  Google Scholar 

  3. Saunders, S. A. et al. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum. 58, 1310–1317 (2008).

    Article  CAS  Google Scholar 

  4. Soubrier, M. et al. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology (Oxford) 48, 1429–1434 (2009).

    Article  CAS  Google Scholar 

  5. Gibofsky, A. & Yazici, Y. Treatment of rheumatoid arthritis: strategies for achieving optimal outcomes. Ann. Rheum. Dis. 69, 941–942 (2010).

    Article  Google Scholar 

  6. Tak, P. P. et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann. Rheum. Dis. 70, 39–46 (2011).

    Article  CAS  Google Scholar 

  7. Yazici, Y. & Yazici, H. Tumor necrosis factor α inhibitors, methotrexate or both? An inquiry into the formal evidence for when they are to be used in rheumatoid arthritis. Clin. Exp. Rheumatol. 26, 449–452 (2008).

    CAS  PubMed  Google Scholar 

  8. Yazici, Y., Adler, N. M. & Yazici, H. Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power considerations. Rheumatology (Oxford) 47, 1054–1057 (2008).

    Article  CAS  Google Scholar 

  9. Paterson, K. R. Events per person year. Can obscure the true risk of certain adverse drug reactions. BMJ 310, 1470 (1995).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Seligman Center for Advanced Therapeutics, NYU Hospital for Joint Diseases, 246 East 20th Street, New York, 10003, NY, USA

    Yusuf Yazici

Authors
  1. Yusuf Yazici
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

Y. Yazici is a consultant for, and has received speakers bureau honoraria from, BMS and Genentech, and is also a consultant for Celgene, Centocor, Merck, Pfizer and UCB.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yazici, Y. When should we use rituximab to treat RA?. Nat Rev Rheumatol 7, 379–380 (2011). https://doi.org/10.1038/nrrheum.2011.79

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2011.79

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing